XKRX214450
Market cap1.78bUSD
Dec 23, Last price
256,500.00KRW
1D
1.18%
1Q
28.51%
Jan 2017
534.90%
IPO
125.79%
Name
PharmaResearch Co Ltd
Chart & Performance
P/E
33.71
P/S
9.89
EPS
7,608.61
Div Yield, %
0.29%
Shrs. gr., 5y
1.54%
Rev. gr., 5y
32.35%
Revenues
261.01b
+34.02%
Net income
76.55b
+88.66%
CFO
64.95b
+9.33%
Dividend
Dec 27, 2023660 KRW/sh
Earnings
Mar 13, 2025
Profile
PharmaResearch Co., Ltd. operates as a biopharmaceutical company in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; Rejuvenex cream, which treats the wound through rapid tissue regeneration; REJURAN HEALER, an intra dermal injection to enhance elasticity, turgidity, and tonicity of skin; Rejuran i and Rejuran s intra dermal or cannula injections; REJURAN moisturizer for daily skin protection; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel; REJURAN healing cream and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. It also provides D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; and CLEVIEL prime plus and contour plus with lidocaine medical devices, as well as CONJURAN medical devices. In addition, the company offers functional foods under the REJULINE, REJUSHINE, and REJULIGHT brands. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Seongnam, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 261,010,911 34.02% | 194,758,644 26.40% | 154,082,898 41.69% | ||||||
Cost of revenue | 132,109,057 | 105,522,831 | 83,417,468 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 128,901,854 | 89,235,813 | 70,665,430 | ||||||
NOPBT Margin | 49.39% | 45.82% | 45.86% | ||||||
Operating Taxes | 23,439,915 | 10,613,904 | 9,209,784 | ||||||
Tax Rate | 18.18% | 11.89% | 13.03% | ||||||
NOPAT | 105,461,939 | 78,621,909 | 61,455,646 | ||||||
Net income | 76,551,214 88.66% | 40,576,699 -13.09% | 46,688,656 42.45% | ||||||
Dividends | (7,529,103) | (6,315,548) | (5,029,864) | ||||||
Dividend yield | 0.65% | 0.91% | 0.61% | ||||||
Proceeds from repurchase of equity | 359,235 | (24,360,900) | |||||||
BB yield | -0.03% | 2.96% | |||||||
| Debt | |||||||||
Debt current | 33,006,061 | 20,574,144 | 20,760,670 | ||||||
Long-term debt | 1,481,343 | 46,194,233 | 44,850,422 | ||||||
Deferred revenue | 835,476 | 1,465,801 | |||||||
Other long-term liabilities | 6,663,909 | 2,210,924 | 1,918,642 | ||||||
Net debt | (244,234,943) | (183,035,266) | (155,577,077) | ||||||
| Cash flow | |||||||||
Cash from operating activities | 64,945,249 | 59,403,808 | 65,297,141 | ||||||
CAPEX | (12,062,682) | (17,757,766) | (23,788,494) | ||||||
Cash from investing activities | (44,667,653) | (11,907,643) | (93,754,918) | ||||||
Cash from financing activities | (25,968,629) | (9,301,361) | 42,965,406 | ||||||
FCF | 55,053,360 | 63,570,103 | 55,138,947 | ||||||
| Balance | |||||||||
Cash | 160,298,060 | 184,343,338 | 156,797,830 | ||||||
Long term investments | 118,424,288 | 65,460,304 | 64,390,339 | ||||||
Excess cash | 265,671,802 | 240,065,710 | 213,484,025 | ||||||
Stockholders' equity | 304,560,417 | 234,324,630 | 190,605,756 | ||||||
Invested Capital | 236,715,954 | 196,174,409 | 198,432,086 | ||||||
ROIC | 48.72% | 39.85% | 33.97% | ||||||
ROCE | 25.66% | 20.55% | 17.96% | ||||||
| EV | |||||||||
Common stock shares outstanding | 10,559 | 9,976 | 10,053 | ||||||
Price | 109,500.00 56.65% | 69,900.00 -14.76% | 82,000.00 43.36% | ||||||
Market cap | 1,156,238,094 65.81% | 697,316,319 -15.41% | 824,317,300 51.59% | ||||||
EV | 957,343,523 | 542,434,045 | 691,656,801 | ||||||
EBITDA | 140,897,450 | 99,982,856 | 80,198,398 | ||||||
EV/EBITDA | 6.79 | 5.43 | 8.62 | ||||||
Interest | 2,987,196 | 3,830,064 | 1,313,688 | ||||||
Interest/NOPBT | 2.32% | 4.29% | 1.86% | ||||||